AlpInvest Partners’s Madrigal Pharmaceuticals MDGL Stock Holding History

AlpInvest Partners’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-42,297	Closed	-$8.98M	–	13
2024 Q3	$8.98M	Sell	42,297 -42,298	-50%	-$10.8M	5.31%	6
2024 Q2	$23.7M	Sell	84,595 -21,149	-20%	-$5.03M	8.5%	6
2024 Q1	$28.2M	Sell	105,744 -105,744	-50%	-$24.9M	11.03%	5
2023 Q4	$48.9M	Buy	+211,488	New	+$37M	11.18%	3

Other funds holding MDGL

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

AlpInvest Partners's MDGL Position: Q4 2024 in Review

AlpInvest Partners sold out of Madrigal Pharmaceuticals (MDGL) in Q4 2024, closing a stake of 42,297 shares — an estimated $8.98M sold.

AlpInvest Partners first reported a position in MDGL in Q4 2023 and held it in 4 quarters. The position peaked at $48.9M in Q4 2023. 283 funds tracked by Wall St. Rank hold MDGL as of Q4 2024.

AlpInvest Partners reported no remaining Madrigal Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
AlpInvest Partners sold 42,297 Madrigal Pharmaceuticals shares in Q4 2024, an estimated $8.98M.
AlpInvest Partners first reported a position in Madrigal Pharmaceuticals in Q4 2023 and held it in 4 quarters.
AlpInvest Partners's Madrigal Pharmaceuticals position peaked at $48.9M in Q4 2023.
283 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2024.

Based on AlpInvest Partners's 13F filing for Q4 2024, filed 13 Feb 2025.